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Background: Pseudoxanthoma elasticum is an inherited disorder that is associated with accumulation of
pathologic elastic fibers in the skin, vascular walls and Bruch’s membrane in the eye. Choroidal neovascularization is
one of the most common causes of acute vision loss in these patients. We report an atypical case of suspected
choroidal neovascularization associated with pseudoxanthoma elasticum.
Case presentation: A 47-year-old Caucasian woman with pseudoxanthoma elasticum and angioid streaks was
referred because of decreased and distorted vision in her right eye of one week’s duration. Visual acuity was 6/12 in
the right eye and 6/6 in the left eye. Fundus examination revealed angioid streaks and white intraretinal macular
deposits bilaterally. Fluorescein angiography did not reveal any obvious leakage in the right eye while optical
coherence tomography revealed subretinal fluid associated with an adjacent intraretinal hyperreflective structure.
Autofluoresence imaging showed focal areas of increased autofluorescence corresponding to the deposits in both
eyes. Over the following year the patient underwent five intravitreal injections of bevacizumab (Genentech/Roche,
US) in the right eye, which resulted in visual acuity improving to 6/9 with regression of the hyperreflective structrure
and complete resolution of subretinal fluid.
Conclusions: Traditionally, fluorescein angiography is effective in the detection of choroidal neovascularization in
patients with pseudoxanthoma elasticum. In our case, optical coherence tomography revealed subretinal fluid and
an adjacent hyperreflective structure while fluorescein angiography did not reveal any obvious leakage. The sole
presence of subretinal fluid does not necessarily imply the presence of choroidal neovascularization and certainly
retinal pigment epithelium dysfunction could also explain subretinal fluid in these patients. However, the complete
absorption of the fluid and the disappearance of the previously evident hyperreflective structure following
treatment, led us to suspect choroidal neovascularization as the primary cause of the above findings. The poor
natural course of choroidal neovascularization in these patients increases the importance of early detection and
should result in the adaptation of a low-threshold strategy concerning the initiation of treatment.
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Figure 1 Red-free and autofluoresence images. Red-free photographs showing angioid streaks and intraretinal macular deposits bilaterally
and fundus autofluoresence images showing focal areas of increased autofluorescence.
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Pseudoxanthoma elasticum (PXE) is an inherited dis-
order that is associated with accumulation of mineral-
ized and fragmented elastic fibers in the skin, vascular
walls and Bruch’s membrane in the eye [1]. ABCC6, an
ATPbinding cassette transporter gene encoding a multi-
drug resistance protein (MRP6), had been identified as
the defective gene [2]. Ocular manifestations include
angioid streaks, peau de orange, optic disc drusen andFigure 2 Fluorescein angiography of the right eye at presentation shcomet lesions [3]. Choroidal neovascularization (CNV)
is one of the most common causes of acute vision loss
in PXE patients [4]. We report the presentation and
management of a case of CNV in a patient with PXE in
whom there was absence of obvious leakage during
fluorescein angiography (FA) and the presence of subret-
inal fluid (SRF) as well as an intraretinal hyper-reflective
structure in spectral-domain optical coherence tomog-
raphy (SD-OCT).owing no obvious leakage.
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A 47 year old Caucasian woman with PXE and angioid
streaks was referred because of decreased and distorted
vision in her right eye (RE) of one week’s duration. At
presentation visual acuity (VA) was 6/12 in the RE and
6/6 in the LE. Fundus examination revealed angioid
streaks and white intraretinal macular deposits bilat-
erally (Figure 1). FA did not reveal any obvious leakageFigure 3 Spectral-domain optical coherence tomography at presenta
tomography of the right eye at presentation showing subretinal fluid and co
(two different horizontal scans are shown) c) Spectral-domain optical cohe
bevacizumab showing resolution of subretinal fluid and absence of the hyp(Figure 2). Contemporaneous SD-OCT revealed SRF
associated with a contiguous hyperreflective structure
suggestive of a Type II CNV, as well as generalized thick-
ening and hyperreflectivity of the outer retina between
the photoreceptor inner/outer segments and retinal pig-
ment epithelium (RPE) bands (Figure 3a,b). Indocyanine
angiography was not performed since the pathology
appeared to be intraretinal and there was no obvioustion and post treatment. a,b) Spectral-domain optical coherence
ntiguous intraretinal hyperreflective material (white arrows)
rence tomography of the right eye after 5 intravitreal injections of
erreflective structure.
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pigment. Fundus autofluoresence showed focal areas of
increased autofluorescence in both eyes (Figure 1). We
obtained informed consent and the patient underwent
five monthly intravitreal injections of bevacizumab
(Genentech/Roche,US) in the RE. After one year of
follow up the fluid did not reappear, and VA improved
to 6/9 with regression of the membrane and resolution
of SRF (Figure 3c). FA at that stage did not reveal any
significant change compared to baseline (Figure 4).
Conclusions
CNV occurs in 72% to 86% of eyes with angioid streaks
and can lead to dramatic visual impairment [4]. Trad-
itionally, FA is effective in the detection of CNV in
patients with PXE, but in some cases prompt diagnosis
could be challenging due to the subtlety or absence of
related signs. In the case presented herein, SD-OCT
revealed SRF and a hyperreflective structure that led to
the suspicion of a Type II CNV. The classic angiographic
appearance of Type II CNV is that of early hyperfluores-
cence [5], and therefore the absence of any obvious leak-
age in the FA was an unexpected finding.
Zweifel et al. recently reported the presence of SRF
not associated with PXE [6]. The authors concluded that
the observed SRF was not associated with CNV, due to
the complete lack of response to intravitreal anti-
vascular endothelial growth factor (VEGF). In contrast to
their findings, in our case SRF responded to anti-VEGF
treatment. Certainly, another pathogenetic mechanism for
the presence of SRF in these patients could be retinal pig-
ment epithelium dysfunction, similarly to chronic serous
chorioretinopathy (CSR). However, anti-VEGF agents haveFigure 4 Fluorescein angiography of the right eye one year after prenot been proven to be efficacious in CSR [7,8] and
therefore the complete absorption of the SRF and the
disappearance of the previously evident hyperreflective
structure following anti-VEGF treatment in our case, led
us to suspect CNV as the primary cause of the above
findings.
The effectiveness of anti-VEGF treatment for CNV
secondary to PXE has been reported in numerous
studies [4,9-14]. Data from these studies indicate that
CNV in these patients is associated with multiple
recurrences and that early treatment seems to be of
great importance. Regular monitoring for long periods
is recommended as well as frequent reinjections at
the slightest signs of CNV activity [11]. Given the
subtly of signs in our case and the heightened sensi-
tivity of SD-OCT, we would recommend the careful
investigation with SD-OCT in the management of
these cases. The poor natural course of CNV in these
patients [15] increases the importance of early detection
and should result in the adaptation of a low-threshold
strategy concerning the initiation of treatment. Our case
demonstrates the importance of SD-OCT in patients with
clinical signs suggesting CNV without corresponding FA
findings.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal. This study
has been reviewed by our institute ethics committee and
therefore was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.sentation with similar appearance as presentation.
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